Skip to main content

Avycaz FDA Approval History

FDA Approved: Yes (First approved February 25, 2015)
Brand name: Avycaz
Generic name: avibactam and ceftazidime
Dosage form: Injection
Company: Actavis Pharma, Inc.
Treatment for: Intraabdominal Infection, Urinary Tract Infection, Pneumonia

Avycaz (avibactam and ceftazidime) is a next generation, non-β lactam β-lactamase inhibitor and third-generation, antipseudomonal cephalosporin antibiotic combination for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia.

Development timeline for Avycaz

DateArticle
Mar 18, 2019Approval Allergan Announces FDA Approval of Avycaz (ceftazidime and avibactam) for Pediatric Patients
Feb  1, 2018Approval FDA Approves Avycaz (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Feb 25, 2015Approval FDA Approves Avycaz (ceftazidime and avibactam) for Complicated Abdominal and Urinary Tract Infections
Dec  5, 2014Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam

See also

Avycaz (avibactam and ceftazidime) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer